Fig. 3.
Fig. 3. One mechanism of granzyme B–independent cytotoxicity involving the Fas pathway. Allospecific day 5 MLR-derived CTLs (H-2b anti–H-2d) from granzyme B+/+ (B+/+), granzyme B−/− (B−/−), and granzyme B−/− × gld/gld (B−/− × g/g) spleens were used against allogeneic TA3 (H-2d) lymphoma cells at a fixed E:T ratio of 10:1 in 51Cr release (A) and 125IUdR release (B) assays. Note that granzyme B−/− and granzyme B−/− × gld/gld CTLs induce essentially normal levels of 51Cr release, whereas both effector populations are unable to mediate any 125I-labeled DNA release at early time points. However, the defective 125I-labeled DNA release is more severe in granzyme B−/− × gld/gld cells than in CTLs deficient for granzyme B alone. Error bars show the range of values at each point. This experiment represents one of four with similar results.

One mechanism of granzyme B–independent cytotoxicity involving the Fas pathway. Allospecific day 5 MLR-derived CTLs (H-2b anti–H-2d) from granzyme B+/+ (B+/+), granzyme B−/− (B−/−), and granzyme B−/− × gld/gld (B−/− × g/g) spleens were used against allogeneic TA3 (H-2d) lymphoma cells at a fixed E:T ratio of 10:1 in 51Cr release (A) and 125IUdR release (B) assays. Note that granzyme B−/− and granzyme B−/− × gld/gld CTLs induce essentially normal levels of 51Cr release, whereas both effector populations are unable to mediate any 125I-labeled DNA release at early time points. However, the defective 125I-labeled DNA release is more severe in granzyme B−/− × gld/gld cells than in CTLs deficient for granzyme B alone. Error bars show the range of values at each point. This experiment represents one of four with similar results.

Close Modal

or Create an Account

Close Modal
Close Modal